"Glycopyrrolate" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A muscarinic antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with some anesthetics.
| Descriptor ID |
D006024
|
| MeSH Number(s) |
D02.092.877.425 D02.675.276.425 D03.383.773.342
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glycopyrrolate".
Below are MeSH descriptors whose meaning is more specific than "Glycopyrrolate".
This graph shows the total number of publications written about "Glycopyrrolate" by people in this website by year, and whether "Glycopyrrolate" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2011 | 1 | 0 | 1 |
| 2016 | 2 | 0 | 2 |
| 2017 | 3 | 0 | 3 |
| 2018 | 2 | 0 | 2 |
| 2019 | 1 | 0 | 1 |
| 2020 | 3 | 0 | 3 |
| 2021 | 6 | 2 | 8 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 1 | 1 |
| 2024 | 0 | 1 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Glycopyrrolate" by people in Profiles.
-
Cardiovascular Events with the Use of Long-Acting Muscarinic Receptor Antagonists: An Analysis of the FAERS Database 2020-2023. Lung. 2024 04; 202(2):119-125.
-
Reducing the Risk of Mortality in Chronic Obstructive Pulmonary Disease With Pharmacotherapy: A Narrative Review. Mayo Clin Proc. 2023 02; 98(2):301-315.
-
Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung Function. N Engl J Med. 2022 09 29; 387(13):1173-1184.
-
Relationship between prior inhaled corticosteroid use and benefits ofbudesonide/glycopyrronium/formoterol fumarate dihydrate on exacerbations, symptoms, health-related quality of life, and lung function in patients with chronic obstructive pulmonary disease: Analyses from the ETHOS study. Respir Med. 2022 06; 197:106857.
-
Anisocoria secondary to antiperspirant wipes in a pediatric population: a case series. J AAPOS. 2022 02; 26(1):42-43.
-
Benefits of budesonide/glycopyrrolate/formoterol fumarate (BGF) on symptoms and quality of life in patients with COPD in the ETHOS trial. Respir Med. 2021 Aug-Sep; 185:106509.
-
Glycopyrrolate does not ameliorate hypothermia associated bradycardia in healthy individuals: A randomized crossover trial. Resuscitation. 2021 07; 164:79-83.
-
Reply to L?pez-Campos et al. and to Rogliani and Calzetta. Am J Respir Crit Care Med. 2021 04 01; 203(7):927-928.
-
Improvement in Lung Function and Patient-Reported Outcomes in Patients with COPD with Comorbid Anxiety and Depression Receiving Nebulized Glycopyrrolate in the GOLDEN 3 and 4 Studies. Int J Chron Obstruct Pulmon Dis. 2021; 16:865-875.
-
Reduced All-Cause Mortality in the ETHOS Trial of Budesonide/Glycopyrrolate/Formoterol for Chronic Obstructive Pulmonary Disease. A Randomized, Double-Blind, Multicenter, Parallel-Group Study. Am J Respir Crit Care Med. 2021 03 01; 203(5):553-564.